Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the safety, tolerance and pharmacokinetics of
HE3286 when administered daily for 28 days to obese adult subjects and to assess potential
activity of HE3286 to decrease insulin resistance. An open-label cohort of 6 patients with
type II diabetes mellitus will be treated at 10 mg (5 mg BID).